Barr Pharmaceuticals Inc
News, chart, profile, more
Last: 67.39-0.35-0.52%4:03pm 08/21/2008Delayed quote data
Add to portfolioAnalyst Create alert
InsiderDiscussFinancials
Sponsored by:
BRL 67.39, -0.35, -0.5%) today announced that its subsidiary, PLIVA - Lachema a.s., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pfizer Inc.'s Aredia(R) (pamindronate disodium) Injection, 30mg/mL, 60mg/mL, and 90mg/mL. The Company plans to launch its product in the fourth quarter of calendar 2008. With this approval, Barr's U.S. generic injectable portfolio now totals eight products.
Barr's generic Aredia (pamindronate disodium) product will compete in a market that had total annual sales of approximately $21 million for the twelve months ended June 2008, based on IMS sales data, wrote in his research note Stock Mania analyst Shah.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment